JNJ-64042056 (Au-001) - Phosphorylated Tau Active Immunotherapy for Preclinical Alzheimer's Disease
Overview
flowchart TD
clinical_trials_nct06544616["nct06544616"]
style clinical_trials_nct06544616 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_0["Trial Details"]
clinical_trials_nct06544616 -->|"includes"| clinical_trials_nct0_0
style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_nct0_1["Mechanism of Action"]
clinical_trials_nct06544616 -->|"includes"| clinical_trials_nct0_1
style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_nct0_2["Phosphorylated Tau as Therapeutic Target"]
clinical_trials_nct06544616 -->|"includes"| clinical_trials_nct0_2
style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_nct0_3["Active Immunotherapy Approach"]
clinical_trials_nct06544616 -->|"includes"| clinical_trials_nct0_3
style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_nct0_4["Rationale for Targeting p-Tau"]
clinical_trials_nct06544616 -->|"includes"| clinical_trials_nct0_4
style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_5["Scientific Background"]
clinical_trials_nct06544616 -->|"includes"| clinical_trials_nct0_5
style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000
...JNJ-64042056 (Au-001) - Phosphorylated Tau Active Immunotherapy for Preclinical Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
JNJ-64042056 (also known as Au-001) is a phosphorylated tau (p-tau) targeted active immunotherapy being developed by Janssen Pharmaceuticals (Johnson & Johnson) for the prevention of Alzheimer's disease. This Phase 2 clinical trial represents a cutting-edge approach to preventing cognitive decline in individuals at risk for AD before symptoms appear.
The trial is evaluating the efficacy, safety, and immunogenicity of JNJ-64042056 in participants with preclinical Alzheimer's disease — individuals who have evidence of AD pathology (amyloid and/or tau) but do not yet show clinical symptoms of cognitive impairment.
This approach represents a paradigm shift from treating symptomatic AD to preventing or delaying the onset of cognitive impairment in at-risk individuals["@novel2024"][@alzheimers2023].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | [NCT06544616](https://clinicaltrials.gov/study/NCT06544616) |
| Phase | Phase 2 |
| Status | Active, Not Recruiting |
| Sponsor | Janssen Pharmaceutica N.V., Belgium |
| Enrollment | 498 participants |
| Study Start Date | July 2024 |
| Estimated Completion | July 2032 |
| Indication | Preclinical Alzheimer's Disease |
| Study Type | Interventional |
| Allocation | Randomized, Double-blind, Placebo-controlled |
Mechanism of Action
Phosphorylated Tau as Therapeutic Target
JNJ-64042056 is designed to generate antibodies that specifically target phosphorylated tau (p-tau) proteins. This represents a more selective approach than first-generation tau immunotherapies that targeted total tau:
- p-tau is pathologically relevant: Phosphorylated tau at specific sites (p-tau181, p-tau217, p-tau231) is specifically found in AD brain lesions, while total tau is elevated in various conditions[@ptau2024]
- Early detection marker: p-tau in CSF and plasma becomes abnormal early in AD pathogenesis, even before clinical symptoms
- Correlation with progression: p-tau levels correlate with cognitive decline and brain atrophy in AD
Active Immunotherapy Approach
Active immunotherapy (vaccination) differs from passive immunotherapy (monoclonal antibodies) in several key ways:
| Feature | Active (JNJ-64042056) | Passive (e.g., Lecanemab) |
|---------|----------------------|---------------------------|
| Administration | Subcutaneous/IM injection | IV infusion |
| Frequency | Less frequent (e.g., annually) | Frequent (e.g., biweekly) |
| Antibody production | Host generates antibodies | Exogenous antibodies delivered |
| Duration of effect | Potentially long-lasting | Requires continuous dosing |
| Immune response | Requires competent immune system | Direct delivery bypasses immunity |
Rationale for Targeting p-Tau
The selective targeting of p-tau provides several advantages[@tauvaccine2023]:
Disease specificity: p-tau is more specific to AD pathology than total tau
Early intervention potential: p-tau changes occur early, enabling prevention strategies
Mechanistic targeting: Antibodies bind to pathological tau species, potentially blocking tau propagation
Safety profile: Reduced risk of targeting normal tau involved in neuronal functionScientific Background
Preclinical Alzheimer's Disease
Preclinical AD represents the earliest stage of Alzheimer's disease, characterized by[@alzheimers2023]:
- Amyloid positivity: Presence of amyloid plaques in the brain (detected via PET or CSF biomarkers)
- Evidence of tau pathology: Elevated p-tau in CSF or early tau PET signal
- Normal cognition: No clinically detectable cognitive impairment on standard tests
- Estimated duration: This stage may last 10-20 years before symptoms appear
The preclinical stage offers a critical window for intervention when pathological burden is still relatively low and neuronal function is preserved.
Tau Biology in AD
The [tau protein](/proteins/tau), encoded by the [MAPT](/genes/mapt) gene, plays essential roles in neuronal function:
- Normal function: Stabilizes microtubules in axons, supporting axonal transport
- Pathological transformation: In AD, tau becomes hyperphosphorylated, leading to:
- Dissociation from microtubules
- Aggregation into neurofibrillary tangles (NFTs)
- Propagation between connected neurons
- Synaptic dysfunction and neuronal loss
Phosphorylation Sites
Key phosphorylation sites targeted by JNJ-64042056 include:
| Site | CSF Abnormality Timeline | Clinical Relevance |
|-----|------------------------|---------------------|
| p-tau181 | Earliest marker, rises ~20 years before onset | Strong predictor of progression |
| p-tau217 | Very early, correlates with amyloid | High specificity for AD |
| p-tau231 | Early marker, linked to tau PET | Associates with cognitive decline |
Study Design
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group clinical trial with a long duration to assess preventive efficacy.
Key Design Features
- Population: Preclinical AD participants (amyloid positive, cognitively normal)
- Randomization: 1:1 active:placebo allocation
- Duration: Up to 206 weeks (~4 years) for efficacy assessment
- Primary endpoint: Change in Preclinical Alzheimer's Disease Cognitive Composite 5 (PACC-5)
Treatment Regimen
Participants receive:
- Active: JNJ-64042056 subcutaneous injections per protocol schedule
- Placebo: Matching placebo injections
Outcome Measures
Primary Endpoints
- PACC-5 Change: Change from baseline in Preclinical Alzheimer's Disease Cognitive Composite 5 at Week 206
Secondary Endpoints
- Clinical progression to MCI or dementia due to AD
- Brain amyloid PET change
- Tau PET change (regional)
- CSF biomarker changes (p-tau181, p-tau217, p-tau231, total tau)
- Plasma biomarker changes
- Safety and tolerability
- Immunogenicity (antibody titers)
Exploratory Endpoints
- Brain volume changes (MRI)
- Functional capacity measures
- Quality of life measures
Clinical Significance
Prevention Paradigm
This trial represents a critical step toward preventive neurology in AD[@aatc2024]:
Treating before symptoms: Intervening before neurodegeneration becomes irreversible
Amyloid-tau sequence: Targeting tau pathology after amyloid removal
Long-term follow-up: Assessing durability of preventive effects
Biomarker-driven: Using biomarkers to identify appropriate participantsComparison to Other Approaches
| Trial | Approach | Target | Population | Stage |
|-------|----------|--------|------------|-------|
| JNJ-64042056 | Active immunotherapy | p-tau | Preclinical AD | Phase 2 |
| Leqembi (lecanemab) | Passive immunotherapy | Aβ aggregate | Early AD | Approved |
| Donanemab | Passive immunotherapy | N3pG Aβ | Early AD | Approved |
| Crenezumab | Passive immunotherapy | Aβ | Preclinical AD (API) | Phase 3 |
Regulatory Considerations
Preventive trials in preclinical populations face unique challenges:
- Long trial duration: Requires years of follow-up
- Large sample sizes: Need to detect subtle cognitive differences
- Ethical considerations: Treating asymptomatic individuals
- Biomarker qualification: Regulatory acceptance of surrogate endpoints
Safety Considerations
Active immunotherapy in healthy(appearing) individuals requires careful safety monitoring:
Common Considerations
- Injection site reactions: Typical with subcutaneous vaccines
- Systemic reactions: Fever, flu-like symptoms
- Autoimmune concerns: Theoretical risk of immune response against normal tau
Monitoring Plan
- Regular neurological examinations
- MRI to detect unexpected brain changes
- Cognitive monitoring for unexpected decline
- Immune response characterization
Related Pages
- [Phosphorylated Tau Biomarkers](/biomarkers/p-tau-181)
- [Phosphorylated Tau (p-tau217)](/biomarkers/p-tau-217)
- [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
- [Preclinical Alzheimer's Disease](/diseases/preclinical-alzheimers)
- [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease-trials)
- [Janssen Neuroscience](/companies/janssen)
- [Tau Protein](/proteins/tau)
- [MAPT Gene](/genes/mapt)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
External Links
- [ClinicalTrials.gov: NCT06544616](https://clinicaltrials.gov/study/NCT06544616)
- [Janssen Pipeline](https://www.janssen.com/pipeline)
- [PubMed Search: JNJ-64042056](https://pubmed.ncbi.nlm.nih.gov/?term=JNJ-64042056)
References
[Smith L, et al, Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[Knopman DS, et al, Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)02346-1)
[Kepp KP, et al, Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)
[Palmqvist S, et al, Cerebrospinal fluid p-tau231: an early biomarker of tau pathology (2024)](https://doi.org/10.1038/s41591-024-01956-3)
[Novak P, et al, Tau immunotherapy: a promising approach for Alzheimer's disease (2023)](https://doi.org/10.1038/s41380-023-01256-x)
[Chen MK, et al, Active tau immunotherapy: mechanisms and clinical outcomes (2024)](https://doi.org/10.1002/alz.13856)
[Janssen Neuroscience Pipeline](https://www.janssen.com/pipeline)